tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Fusion Antibodies plc Successfully Passes AGM Resolutions

Story Highlights
Fusion Antibodies plc Successfully Passes AGM Resolutions

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Fusion Antibodies Plc ( (GB:FAB) ) just unveiled an update.

Fusion Antibodies plc announced that all resolutions were passed at its recent annual general meeting. This development underscores the company’s stable governance and continued focus on advancing its strategic goals in the rapidly growing monoclonal antibody therapeutics market, which is projected to surpass $445 billion by 2028.

The most recent analyst rating on (GB:FAB) stock is a Hold with a £16.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.

Spark’s Take on GB:FAB Stock

According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.

Fusion Antibodies Plc’s overall stock score is primarily impacted by its weak financial performance, characterized by significant losses and cash flow issues. While technical indicators suggest a positive trend, the negative valuation metrics further weigh down the score. The absence of earnings call data and corporate events leaves the financial and technical aspects as the primary influences.

To see Spark’s full report on GB:FAB stock, click here.

More about Fusion Antibodies Plc

Fusion Antibodies plc is a Belfast-based contract research organization specializing in pre-clinical antibody discovery, engineering, and supply for therapeutic drug and diagnostic applications. Established in 2001 as a spin-out from Queen’s University Belfast, the company offers a wide range of services including antibody generation, development, production, characterization, and optimization. Fusion Antibodies serves an international client base, including eight of the top 10 global pharmaceutical companies, and aims to accelerate drug development through innovative platforms.

Average Trading Volume: 1,663,026

Technical Sentiment Signal: Buy

Current Market Cap: £15.06M

Find detailed analytics on FAB stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1